The National Pharmaceutical Regulatory Agency (NPRA) Malaysia has approved Spesolimab (marketed as SPEVIGO®) for the treatment of flares in adults with generalized pustular psoriasis (GPP), the first indicated treatment of its kind in Malaysia.
Log In or Register as a healthcare professional to read the full article.
